Related News for SYNGENE

Syngene Q4 Results: Net profit rises 6% to Rs 189 crore, revenue drops 8%

 24 Apr 09:56 PM

The earnings before interest, tax, depreciation and ammortisation dropped 1% YoY to Rs. 333 crore in Q4FY24. The EBITDA margin rose 300 basis points YoY to 36%.

SYNGENE INTERNATIONAL: CO RECOMMENDED A FINAL DIVIDEND OF 1.25 RUPEES PER EQUITY SHARE

 24 Apr 08:55 PM

SYNGENE INTERNATIONAL: CO RECOMMENDED A FINAL DIVIDEND OF 1.25 RUPEES PER EQUITY SHARE

SYNGENE INTERNATIONAL: Q4 EBITDA 3.17B RUPEES VS 3.14B (YOY) || Q4 EBITDA MARGIN 34.56% VS 31.59% (YOY)

 24 Apr 08:55 PM

SYNGENE INTERNATIONAL: Q4 EBITDA 3.17B RUPEES VS 3.14B (YOY) || Q4 EBITDA MARGIN 34.56% VS 31.59% (YOY)

SYNGENE INTERNATIONAL: Q4 CONS NET PROFIT 1.89B RUPEES VS 1.79B (YOY); 1.12B (QOQ) || Q4 REVENUE 9.17B RUPEES VS 9.94B (YOY); 8.54B (QOQ)

 24 Apr 08:55 PM

SYNGENE INTERNATIONAL: Q4 CONS NET PROFIT 1.89B RUPEES VS 1.79B (YOY); 1.12B (QOQ) || Q4 REVENUE 9.17B RUPEES VS 9.94B (YOY); 8.54B (QOQ)

Trade Spotlight | Your strategy to deal in Syngene International, IRCTC, CDSL today

 15 Apr 05:58 AM

CDSL formed robust bullish candlestick pattern on the daily charts with strong volumes. The stock has seen a decisive breakout of consolidation of the recent past sessions and traded well above key moving averages.

Goldman picks 2 pharma stocks, screams sells on Laurus Labs

 12 Apr 11:10 AM

Global broking firm Goldman Sachs on Friday initiated coverage on Syngene International and Neuland Labs with buy ratings but gave a sell call on Laurus Labs.

Positive Breakout: Syngene International and 2 other stocks cross above their 200 DMA

 12 Feb 08:20 AM

For more such web stories click on the ET

F&O stocks to buy today: Trent, Apollo Tyre among top 9 trading ideas for 31 January 2024

 31 Jan 09:30 AM

Positive setup was seen in stocks like Syngene, HPCL, BHEL, LIC Housing Finance, Bosch Ltd, DLF, Tata Motors, BPCL, PNB, MGL, Manappuram Finance, Bank of Baroda, Birla Soft, HAL and Zydus Life.

No change in 30% EBITDA margin guidance or long-term investment plan: Jonathan Hunt, Syngene

 29 Jan 10:36 AM

Syngene International, led by Jonathan Hunt, MD & CEO, remains committed to its long-term investment plans despite a guidance cut. The company experienced a slight softness in Q3 but expects it to be a temporary trend in the US biotech segment due to a slowdown in funding. The EBITDA margin guidance of around 30% remains unchanged, and the company is confident in its strong margin structure. As for capex guidance, the company adjusted it to $60 million for the year, with $40 million already invested and $20 million to be completed in the current quarter.

Syngene Intl Consolidated December 2023 Net Sales at Rs 853.50 crore, up 8.6% Y-o-Y

 29 Jan 10:22 AM

NULL